Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读

2017-11-30 中国循证医学杂志.2017,17(11):1260-1264.

心脏瓣膜病解读

2017年3月和 9月，美国 AHA/ACC 及欧洲 ESC/EACTs 分别推出了心脏瓣膜疾病管理指南更新。这些指南的更新以 TAVI相关内容为主，涵盖心脏瓣膜疾病危险分层、主动脉疾病干预选择、人工瓣膜植入术后抗血栓治疗等方面。本文将主要围绕主动脉瓣狭窄（aortic valve stenosis，AS）治疗的更新内容，对比 2017 年 AHA/ACC 与ESC/EACTs 心脏瓣膜疾病管理指

中文标题：

2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读

发布机构：

发布日期：

2017-11-30

简要介绍：

2017年3月和 9月，美国 AHA/ACC 及欧洲 ESC/EACTs 分别推出了心脏瓣膜疾病管理指南更新。这些指南的更新以 TAVI相关内容为主，涵盖心脏瓣膜疾病危险分层、主动脉疾病干预选择、人工瓣膜植入术后抗血栓治疗等方面。本文将主要围绕主动脉瓣狭窄（aortic valve stenosis，AS）治疗的更新内容，对比 2017 年 AHA/ACC 与ESC/EACTs 心脏瓣膜疾病管理指南的异同，并对热点问题作出解读。

作者： 四川大学华西医院心脏内科 欧袁伟翔 李怡坚 陈茂

 

拓展指南：与心脏瓣膜相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读)] GetToolGuiderByIdResponse(projectId=1, id=e413f1c00153a835, title=2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读, enTitle=, guiderFrom=中国循证医学杂志.2017,17(11):1260-1264., authorId=null, author=, summary=2017年3月和 9月，美国 AHA/ACC 及欧洲 ESC/EACTs 分别推出了心脏瓣膜疾病管理指南更新。这些指南的更新以 TAVI相关内容为主，涵盖心脏瓣膜疾病危险分层、主动脉疾病干预选择、人工瓣膜植入术后抗血栓治疗等方面。本文将主要围绕主动脉瓣狭窄（aortic valve stenosis，AS）治疗的更新内容，对比 2017 年 AHA/ACC 与ESC/EACTs 心脏瓣膜疾病管理指, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Nov 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年3月和 9月，美国 AHA/ACC 及欧洲 ESC/EACTs 分别推出了心脏瓣膜疾病管理指南更新。这些指南的更新以 TAVI相关内容为主，涵盖心脏瓣膜疾病危险分层、主动脉疾病干预选择、人工瓣膜植入术后抗血栓治疗等方面。本文将主要围绕主动脉瓣狭窄（aortic valve stenosis，AS）治疗的更新内容，对比 2017 年 AHA/ACC 与ESC/EACTs 心脏瓣膜疾病管理指南的异同，并对热点问题作出解读。 </P>作者： 四川大学华西医院心脏内科 欧袁伟翔 李怡坚 陈茂 <P> </P>拓展指南：<strong>与<font color=red>心脏瓣膜</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=239281c00151e6c5" title="2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗" target=_blank>2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=6b2e81c001398a82" title="【精品指南】2014版与2017版心脏瓣膜病管理指南内容对比" target=_blank>【精品指南】2014版与2017版心脏瓣膜病管理指南内容对比</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=dc65a1c0013983cb" title="2014版与2017版心脏瓣膜病管理指南内容比较" target=_blank>2014版与2017版心脏瓣膜病管理指南内容比较</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=d57ee1c00139a44d" title="2017 AHA/ACC指南：心脏瓣膜病患者的管理（更新版）" target=_blank>2017 AHA/ACC指南：心脏瓣膜病患者的管理（更新版）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=a175f1c001382e35" title="【合集】ASE及AHA/ACC心脏瓣膜病相关指南中文版翻译合集" target=_blank>【合集】ASE及AHA/ACC心脏瓣膜病相关指南中文版翻译合集</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E5%BF%83%E8%84%8F%E7%93%A3%E8%86%9C" target=_blank>有关心脏瓣膜更多指南</a></ul>, tagList=[TagDto(tagId=1639, tagName=心脏瓣膜病), TagDto(tagId=1818, tagName=解读)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8306, appHits=488, showAppHits=0, pcHits=6013, showPcHits=2765, likes=152, shares=14, comments=4, approvalStatus=1, publishedTime=Fri Dec 22 16:56:13 CST 2017, publishedTimeString=2017-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Dec 22 16:56:13 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 23:29:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读)])
2017年ESC/EACTs与AHA/ACC心脏瓣膜疾病管理的指南解读
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=907254, encodeId=7fd690e2546f, content=好，研读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er0R00OsOXnfRNSzefL1GE8gVrN5H08v8tCls8N8nUXGibIFZibo568AI7wicNQ65ZRgppZ93lY5lKRg/132, createdBy=3b845320921, createdName=drcr7, createdTime=Sat Dec 12 10:25:27 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898778, encodeId=097e898e789e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo6TpEicHF74hfFQE9nHluOVicqxZGAoQYkib8hvCyRloOqMKicyjByTodWGo172lrIC8s92ZPQbLAOlQ/132, createdBy=fcfe2521163, createdName=苏可٩( ö̆ ) و, createdTime=Thu Nov 12 19:15:18 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805723, encodeId=ad30805e232c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/6vvZFcN0LPeOjzUQWAvgWz2QRvSTwajva4TibZ9KNsrJmoDMiaqZ7bpwLkEERyGicX7Jhl1rerUVgbUJw9T6wyvKA/0, createdBy=f15a2224713, createdName=徐浩然, createdTime=Sun Aug 02 10:38:52 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271600, encodeId=a7082e16009f, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Dec 22 19:42:28 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2020-12-12 drcr7

    好，研读！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=907254, encodeId=7fd690e2546f, content=好，研读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er0R00OsOXnfRNSzefL1GE8gVrN5H08v8tCls8N8nUXGibIFZibo568AI7wicNQ65ZRgppZ93lY5lKRg/132, createdBy=3b845320921, createdName=drcr7, createdTime=Sat Dec 12 10:25:27 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898778, encodeId=097e898e789e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo6TpEicHF74hfFQE9nHluOVicqxZGAoQYkib8hvCyRloOqMKicyjByTodWGo172lrIC8s92ZPQbLAOlQ/132, createdBy=fcfe2521163, createdName=苏可٩( ö̆ ) و, createdTime=Thu Nov 12 19:15:18 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805723, encodeId=ad30805e232c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/6vvZFcN0LPeOjzUQWAvgWz2QRvSTwajva4TibZ9KNsrJmoDMiaqZ7bpwLkEERyGicX7Jhl1rerUVgbUJw9T6wyvKA/0, createdBy=f15a2224713, createdName=徐浩然, createdTime=Sun Aug 02 10:38:52 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271600, encodeId=a7082e16009f, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Dec 22 19:42:28 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2020-11-12 苏可٩( ö̆ ) و

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=907254, encodeId=7fd690e2546f, content=好，研读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er0R00OsOXnfRNSzefL1GE8gVrN5H08v8tCls8N8nUXGibIFZibo568AI7wicNQ65ZRgppZ93lY5lKRg/132, createdBy=3b845320921, createdName=drcr7, createdTime=Sat Dec 12 10:25:27 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898778, encodeId=097e898e789e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo6TpEicHF74hfFQE9nHluOVicqxZGAoQYkib8hvCyRloOqMKicyjByTodWGo172lrIC8s92ZPQbLAOlQ/132, createdBy=fcfe2521163, createdName=苏可٩( ö̆ ) و, createdTime=Thu Nov 12 19:15:18 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805723, encodeId=ad30805e232c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/6vvZFcN0LPeOjzUQWAvgWz2QRvSTwajva4TibZ9KNsrJmoDMiaqZ7bpwLkEERyGicX7Jhl1rerUVgbUJw9T6wyvKA/0, createdBy=f15a2224713, createdName=徐浩然, createdTime=Sun Aug 02 10:38:52 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271600, encodeId=a7082e16009f, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Dec 22 19:42:28 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2020-08-02 徐浩然

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=907254, encodeId=7fd690e2546f, content=好，研读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er0R00OsOXnfRNSzefL1GE8gVrN5H08v8tCls8N8nUXGibIFZibo568AI7wicNQ65ZRgppZ93lY5lKRg/132, createdBy=3b845320921, createdName=drcr7, createdTime=Sat Dec 12 10:25:27 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898778, encodeId=097e898e789e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo6TpEicHF74hfFQE9nHluOVicqxZGAoQYkib8hvCyRloOqMKicyjByTodWGo172lrIC8s92ZPQbLAOlQ/132, createdBy=fcfe2521163, createdName=苏可٩( ö̆ ) و, createdTime=Thu Nov 12 19:15:18 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805723, encodeId=ad30805e232c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/6vvZFcN0LPeOjzUQWAvgWz2QRvSTwajva4TibZ9KNsrJmoDMiaqZ7bpwLkEERyGicX7Jhl1rerUVgbUJw9T6wyvKA/0, createdBy=f15a2224713, createdName=徐浩然, createdTime=Sun Aug 02 10:38:52 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271600, encodeId=a7082e16009f, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Dec 22 19:42:28 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2017-12-22 131****1460

    学习了受益匪浅

    0

相关指南

2017 EHRA/ESC共识文件：心脏瓣膜病相关性房颤的抗栓治疗

欧洲心律学会(EHRA,European Heart Rhythm Association) · 2017-11-01

【合集】ASE及AHA/ACC心脏瓣膜病相关指南中文版翻译合集

暂未更新 · 2017-03-03

2014 年美国心脏瓣膜病指南解读

美国心脏协会(AHA,American Heart Association) · 2015-09-30

EAE/ASE 超声心动图在心脏瓣膜病经导管介入治疗新技术中应用的建议

美国超声心动图学会(ASE,American Society of Echocardiography) · 2011-09-01

Baidu
map
Baidu
map
Baidu
map